Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


11.03.2019

4 Anticancer Res
1 Arch Bronconeumol
1 BMC Cancer
3 Cancer
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Res
5 Cancer Sci
1 Chest
1 Clin Cancer Res
1 Clin Lung Cancer
1 Clin Nucl Med
1 Eur J Cardiothorac Surg
2 Int J Cancer
2 Int J Oncol
3 J Cancer Res Clin Oncol
1 J Thorac Cardiovasc Surg
7 J Thorac Oncol
1 Lancet Respir Med
1 Mol Carcinog
2 Oncogene
2 Oncol Rep
1 Oncologist
1 PLoS Genet


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res


  1. Oxford Case Histories in Lung Cancer.
    Anticancer Res. 2019;39:1633.
    PubMed     Text format    

  2. NAKASHIMA K, Akamatsu H, Murakami H, Niwa T, et al
    Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1463-1468.
    PubMed     Text format     Abstract available

  3. KASAHARA N, Sunaga N, Tsukagoshi Y, Miura Y, et al
    Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1.
    Anticancer Res. 2019;39:1455-1461.
    PubMed     Text format     Abstract available

  4. ORTEGA-GRANADOS AL, Artal-Cortes A, Aguiar-Bujanda D, Oramas J, et al
    Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1317-1328.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  5. SEIJO LM, Peces-Barba G
    Inhaled Corticosteroids and Lung Cancer in COPD.
    Arch Bronconeumol. 2019 Mar 2. pii: S0300-2896(19)30068.
    PubMed     Text format    


    BMC Cancer

  6. ZHAO P, Wu J, Lu F, Peng X, et al
    The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
    BMC Cancer. 2019;19:201.
    PubMed     Text format     Abstract available


    Cancer

  7. SINGH N, Baldi M, Kaur J, Muthu V, et al
    Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
    Cancer. 2019 Mar 2. doi: 10.1002/cncr.32028.
    PubMed     Text format     Abstract available

  8. GILL HS, Ramalingam SS
    A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.
    Cancer. 2019 Mar 2. doi: 10.1002/cncr.31996.
    PubMed     Text format    

  9. PRINTZ C
    Study projects a 43% increase in lung cancer mortality among women: New research suggests that, among women, strides in reducing global deaths from breast cancer could be tempered by rising lung cancer deaths. However, according to experts, the projec
    Cancer. 2019;125:831-832.
    PubMed     Text format    


    Cancer Epidemiol Biomarkers Prev

  10. MAGUIRE FB, Morris CR, Parikh-Patel A, Cress RD, et al
    Disparities in systemic treatment use in advanced-stage non-small cell lung cancer by source of health insurance.
    Cancer Epidemiol Biomarkers Prev. 2019 Mar 6. pii: 1055-9965.EPI-18-0823.
    PubMed     Text format     Abstract available


    Cancer Res

  11. UDYAVAR AR, Wooten DJ, Hoeksema M, Bansal M, et al
    Correction: Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.
    Cancer Res. 2019;79:1014.
    PubMed     Text format    


    Cancer Sci

  12. ZHA L, Kitamura Y, Kitamura T, Liu R, et al
    Population-based cohort study on health effects of asbestos exposure in Japan.
    Cancer Sci. 2019;110:1076-1084.
    PubMed     Text format     Abstract available

  13. NISHIO M, Takahashi T, Yoshioka H, Nakagawa K, et al
    KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
    Cancer Sci. 2019;110:1012-1020.
    PubMed     Text format     Abstract available

  14. IEGUCHI K, Maru Y
    Roles of EphA1/A2 and ephrin-A1 in cancer.
    Cancer Sci. 2019;110:841-848.
    PubMed     Text format     Abstract available

  15. GUO R, Li Y, Wang Z, Bai H, et al
    HIF-1alpha and NF-kappaB play important roles in regulating PD-L1 expression by EGFR mutants in non-small cell lung cancer cells.
    Cancer Sci. 2019 Mar 7. doi: 10.1111/cas.13989.
    PubMed     Text format     Abstract available

  16. MIYAUCHI E, Matsuda T, Kiyotani K, Low SK, et al
    Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations.
    Cancer Sci. 2019;110:867-874.
    PubMed     Text format     Abstract available


    Chest

  17. BADE BC, Silvestri GA
    Setting the Stage for Success in Lung Cancer: The Importance of Remembering Your (Guide)Lines.
    Chest. 2019;155:456-457.
    PubMed     Text format    


    Clin Cancer Res

  18. DOROSHOW DB, Sanmamed MF, Hastings K, Politi K, et al
    Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-1538.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  19. WU YL, Herbst RS, Mann H, Rukazenkov Y, et al
    ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
    Clin Lung Cancer. 2018;19:e533-e536.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  20. DEJANOVIC D, Amtoft AG, Sorensen JB, Pohl M, et al
    18F-FDG PET/CT Findings in Disseminated Genital Herpes in an Immunocompetent Patient With Anaplastic Lymphoma Kinase Rearranged Advanced Nonsmall Cell Lung Cancer.
    Clin Nucl Med. 2019 Mar 1. doi: 10.1097/RLU.0000000000002523.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  21. BENDIXEN M, Kronborg C, Jorgensen OD, Andersen C, et al
    Cost-utility analysis of minimally invasive surgery for lung cancer: a randomized controlled trial.
    Eur J Cardiothorac Surg. 2019 Mar 5. pii: 5369803. doi: 10.1093.
    PubMed     Text format     Abstract available


    Int J Cancer

  22. NARDI I, Reno T, Yun X, Sztain T, et al
    Triptolide inhibits Wnt signaling in NSCLC through upregulation of multiple Wnt inhibitory factors via epigenetic modifications to Histone H3.
    Int J Cancer. 2018;143:2470-2478.
    PubMed     Text format     Abstract available

  23. ZHENG S, Luo X, Dong C, Zheng D, et al
    A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
    Int J Cancer. 2018;143:2592-2601.
    PubMed     Text format     Abstract available


    Int J Oncol

  24. LIU S, Tang H, Zhu J, Ding H, et al
    High expression of Copine 1 promotes cell growth and metastasis in human lung adenocarcinoma.
    Int J Oncol. 2018;53:2369-2378.
    PubMed     Text format     Abstract available

  25. ZHANG C, Hao Y, Wu L, Dong X, et al
    Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma.
    Int J Oncol. 2018;53:2531-2541.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  26. CAMPLING BG, Ye Z, Lai Y, Li L, et al
    Disparity in age at lung cancer diagnosis between current and former smokers.
    J Cancer Res Clin Oncol. 2019 Mar 4. pii: 10.1007/s00432-019-02875.
    PubMed     Text format     Abstract available

  27. SONG Q, Shang J, Zhang C, Zhang L, et al
    Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in NSCLC patients.
    J Cancer Res Clin Oncol. 2019;145:737-746.
    PubMed     Text format     Abstract available

  28. ZHANG Y, Ma Y, Li Y, Shen X, et al
    Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations.
    J Cancer Res Clin Oncol. 2019;145:747-757.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  29. SALTER KD, Burt BM
    Commentary: Postoperative blood transplantation for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2019 Jan 25. pii: S0022-5223(19)30259.
    PubMed     Text format    


    J Thorac Oncol

  30. SHUKUYA T, Yamada T, Koenig MJ, Xu J, et al
    The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non-small cell lung cancer.
    J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30150.
    PubMed     Text format     Abstract available

  31. HO C
    Anticipating the Next Step in the Management of ALK-Positive NSCLC.
    J Thorac Oncol. 2018;13:595-597.
    PubMed     Text format    

  32. ROSSI A, Novello S
    The Tradition of the Rising Sun: When Geography Counts.
    J Thorac Oncol. 2018;13:598-600.
    PubMed     Text format    

  33. MIYAWAKI E, Murakami H, Takahashi T
    Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma.
    J Thorac Oncol. 2018;13:e79-e81.
    PubMed     Text format    

  34. RANGACHARI D, VanderLaan PA, Costa DB
    Updated Correlation of 22C3-PD-L1 >/=50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting.
    J Thorac Oncol. 2018;13:e81-e83.
    PubMed     Text format    

  35. TANIZAKI J, Chiba Y, Haratani K, Hayashi H, et al
    In Reply.
    J Thorac Oncol. 2018;13:e86-e87.
    PubMed     Text format    

  36. DZIADZIUSZKO R, Smit EF, Dafni U, Wolf J, et al
    Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP).
    J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30148.
    PubMed     Text format     Abstract available


    Lancet Respir Med

  37. SCHOFFSKI P, Sufliarsky J, Gelderblom H, Blay JY, et al
    Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, p
    Lancet Respir Med. 2018;6:431-441.
    PubMed     Text format     Abstract available


    Mol Carcinog

  38. HAN X, Dong Q, Wu J, Luo Y, et al
    RASSF10 suppresses lung cancer proliferation and invasion by decreasing the level of phosphorylated LRP6.
    Mol Carcinog. 2019 Mar 4. doi: 10.1002/mc.23000.
    PubMed     Text format     Abstract available


    Oncogene

  39. CROSSLAND DL, Denning WL, Ang S, Olivares S, et al
    Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
    Oncogene. 2018;37:3686-3697.
    PubMed     Text format     Abstract available

  40. TANG Q, Lu J, Zou C, Shao Y, et al
    CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis.
    Oncogene. 2018;37:3617-3630.
    PubMed     Text format     Abstract available


    Oncol Rep

  41. DU M, Wang J, Chen H, Wang S, et al
    MicroRNA200a suppresses migration and invasion and enhances the radiosensitivity of NSCLC cells by inhibiting the HGF/cMet signaling pathway.
    Oncol Rep. 2019;41:1497-1508.
    PubMed     Text format     Abstract available

  42. ZHANG L, Zhang T, Deng Z, Sun L, et al
    MicroRNA3653 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting ITGB1.
    Oncol Rep. 2019;41:1669-1677.
    PubMed     Text format     Abstract available


    Oncologist

  43. PASELLO G, Vicario G, Zustovich F, Oniga F, et al
    From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).
    Oncologist. 2019 Mar 7. pii: theoncologist.2018-0712.
    PubMed     Text format     Abstract available


    PLoS Genet

  44. WILK G, Braun R
    regQTLs: Single nucleotide polymorphisms that modulate microRNA regulation of gene expression in tumors.
    PLoS Genet. 2018;14:e1007837.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: